Dan Stanton, Managing editor

March 19, 2019

3 Min Read
Lonza’s POC CAR-T tech: Out with the cleanroom, in with the Cocoon
Lonza's autologous point-of-care cell therapy tech. Image c/o Lonza

Lonza will provide its point-of-care (POC) Cocoon cell therapy platform to the Sheba Medical Center in Israel to provide automated and closed CAR-T manufacturing.

The collaboration between Sheba and Swiss contract development and manufacturing organization (CDMO) Lonza aims to confirm the benefits of using the Cocoon system to make autologous cell therapies in a POC environment.

“The partnership with Sheba will test the Cocoon in the clinical setting,” Eytan Abraham, head of Personalized Medicine at Lonza Pharma Biotech, told Bioprocess Insider.


Lonza’s autologous point-of-care cell therapy tech. Image c/o Lonza

“In this regard we will be creating cassettes for their CAR [chimeric antigen receptor] T process and training their staff to use the Cocoon. Our goal is to bring safe and efficient autologous manufacturing to customers – both clinical centers and pharma and biotech companies – enabling them to treat more patients and reduce the costs of goods.”

Cocoon system

Octane Biotech developed the Cocoon system. Lonza has worked with the firm since 2015 to help develop the platform for autologous cell therapy manufacturing, and last October acquired an 80% stake in the firm. The CDMO now has a controlling stake in what it described at the time as a “game changer” in the autologous cell therapy space.

The platform is a single system that can be used for a variety of different autologous cell therapy protocols, including CAR-T, but also tumor-infiltrating lymphocytes (TILs) and Mesenchymal stem cells (MSCs), Abraham said.

“Each patient batch is produced in a single disposable cassette customized to their specific CAR T process. A typical manual process would have over 10 handling steps – the Cocoon technology  automates the stages from activation, through transduction, expansion and harvest and drastically reduces the handling and therefore makes manufacturing more efficient.”

The system has been integrated into Lonza’s cell and gene therapy offering and brought into the firm’s Houston site.


A mock up of the Cocoon multiplex ‘orchard’ c/o Lonza


According to Abraham, the platform offers advantages including increased number of unit operations in one system, faster process set-up due to its plug and play cassette, reduced clean room space required and reduced staff for handling.

“The system also has greater flexibility as the cassette is bespoke and specific to the process. Combining operations in one system also simplifies the data tracking and collection which means complete sample and product traceability.”

Much of the talk about reducing cost of autologous cell therapies has centered around the need for fully-closed and automated systems. While no system is yet to be fully closed or automated, the Cocoon system moves towards this ideal, Abraham said.

“Most processes are incorporated but some may have some manual handling phases (eg. selection). This still provides a significantly more efficient process than fully manual processes and other automated processes, and we are working to incorporate additional key capabilities into the Cocoon.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like